The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Policy symposium in Hyderabad focuses on life skills education and community?driven solutions
The programme integrates simulation-based training, expert-led sessions, and case-based discussions
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
Subscribe To Our Newsletter & Stay Updated
